In 2019 there was one approved oral peptide drug worth paying attention to. Today there are several, and 2025 was the year the platform stopped being a curiosity. Oral semaglutide proved cardiovascular benefit in the SOUL trial, Eli Lilly's orforglipron cleared Phase 3, Entera Bio is moving an oral parathyroid hormone tablet into a registrational program, and Rani Therapeutics raised over a billion dollars on a swallowable microneedle capsule.
So yes, oral peptides are here. But "here" does not mean what most marketing pages claim, and the gap between what is clinically validated and what gets sold in capsules on the gray market is wider than the headlines suggest. This is what the oral peptide era actually looks like right now, what is coming next, and what it does and does not mean for compounds like BPC-157, KPV, TB-500, and GHK-Cu.
Why peptides have always been injected
Peptides are chains of amino acids. The gastrointestinal tract is designed to break chains of amino acids apart. Gastric pH sits between 1 and 3, which hydrolyzes peptide bonds. Pepsin, trypsin, chymotrypsin, and elastase finish the job. Even if a peptide survives the acid and the enzymes, it still has to cross an unstirred mucus layer, slip between or through intestinal epithelial cells, and then avoid first-pass metabolism in the liver.
The result is brutal. Native oral bioavailability for most therapeutic peptides sits under 0.1 percent. Subcutaneous semaglutide, by comparison, is absorbed at roughly 89 percent. That gap, almost three orders of magnitude, is the entire reason injections have been the default route for peptide drugs for decades.
The only way to close it is to fix the delivery problem for one molecule at a time. There is no generic "oral peptide" technology. Each program picks a target, then invents the chemistry to get that specific molecule across the gut wall intact.
The drugs that proved it works
A handful of oral peptide drugs are already on the market. Each one solved the delivery problem in a different way.
Rybelsus (oral semaglutide, 2019) is the big one. Novo Nordisk co-formulates semaglutide with a permeation enhancer called SNAC, short for sodium N-(8-[2-hydroxybenzoyl]amino)caprylate. SNAC does three things at once in the stomach. It buffers local pH upward, protecting semaglutide from pepsin. It monomerizes semaglutide by changing solvent polarity, breaking up oligomers into absorbable single molecules. And it briefly fluidizes the gastric epithelial cell membrane, letting semaglutide slip across and enter circulation. The effect on the membrane is fully reversible. Absorption happens in the stomach, not the intestine, which is unusual. Bioavailability ends up around 0.4 to 1 percent, which is 90 times lower than the subcutaneous version but high enough to matter if you dose up to compensate. Patients have to take it on an empty stomach with no more than four ounces of water, then wait at least 30 minutes before eating, drinking, or taking other medications.
Mycapssa (oral octreotide, 2020) is the first oral somatostatin analog. Chiasma, now part of Amryt, uses a different permeation enhancer platform called TPE, or Transient Permeability Enhancer, built around sodium caprylate. Mycapssa is approved for acromegaly maintenance in patients who have already responded to injectable octreotide. It is not a weight loss drug, but it is a clean proof of concept that the oral peptide category extends beyond GLP-1s.
Linaclotide (Linzess) and plecanatide (Trulance) are guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation. They are deliberately designed to stay in the gut lumen with near-zero systemic absorption. Low bioavailability is the design feature, not a flaw. They activate receptors on the inside of the intestine to drive fluid secretion, and the fact that almost none of the drug gets into the bloodstream is a safety advantage. Worth knowing about because they are technically oral peptides and they work, just under a completely different paradigm from Rybelsus.
Cyclosporine is the textbook case. It is a cyclic peptide, not a linear chain, and the cyclic structure plus several N-methylated amino acids give it a chameleonic conformation that is stable in the gut and absorbable across the intestinal wall. Depending on the formulation, oral bioavailability runs anywhere from 20 to 70 percent. Every oral peptide chemistry team studies cyclosporine because it represents what is possible when a peptide has the right backbone.
Desmopressin rounds out the list. It has been available as oral tablets and sublingual melts for decades. Bioavailability is only about 0.1 to 0.25 percent, but desmopressin is potent enough at low plasma levels that this works clinically for nocturia, diabetes insipidus, and nocturnal enuresis.
The 2025 turning point
For years the knock on Rybelsus was that it had not been tested in the long, hard-outcomes trials that validated injectable GLP-1s. That changed in March 2025 with the SOUL trial published in the New England Journal of Medicine.
SOUL enrolled 9,650 adults with type 2 diabetes plus established cardiovascular disease, chronic kidney disease, or both. The primary endpoint was major adverse cardiovascular events, meaning cardiovascular death, nonfatal heart attack, or nonfatal stroke. Over a median follow-up of 49.5 months, oral semaglutide reduced those events by 14 percent compared with placebo, with a hazard ratio of 0.86 and a p value of 0.006.
A 14 percent relative reduction in hard cardiovascular endpoints is the same class of result that made injectable semaglutide the standard of care. It means oral semaglutide is not just a convenience version. It is on the same evidence tier as the injection. It also means the platform works, not just the molecule. If you can get a GLP-1 across the gut wall reliably with SNAC, you can probably do the same trick with other peptides, and the safety and efficacy signal will track.
That is the real 2025 inflection point. Oral peptides stopped being a curiosity.
The pipeline most people are not watching
Three programs are worth tracking right now.
Orforglipron (Eli Lilly) just finished Phase 3. In ATTAIN-1, patients with obesity lost about 27 pounds on average at 72 weeks, roughly 12 percent of baseline weight. In ATTAIN-2, patients with type 2 diabetes and obesity lost about 23 pounds with an A1C reduction of 1.8 percent. There are no food or water restrictions. You take it and go on with your day. Lilly is preparing submissions in obesity and type 2 diabetes.
Important distinction that most articles get wrong: orforglipron is a small molecule, not a peptide. It is designed to activate the GLP-1 receptor the same way a peptide does, but it is built out of a different kind of chemistry entirely. That is how it side-steps the oral peptide delivery problem. It is not a peptide trying to cross the gut, it is a small molecule that crosses the gut the way small molecules always have. If it launches on schedule, it will take a large bite out of the injectable GLP-1 market, but it should not be counted as a win for oral peptide delivery technology.
Entera Bio EB613 is a more interesting story for the peptide community. It is an oral tablet of parathyroid hormone fragment 1-34, the same active ingredient as Forteo, an injectable used for severe osteoporosis. Entera's Phase 2 study in 161 postmenopausal women hit endpoints for bone mineral density and bone formation markers. The company then met with the FDA for an end-of-Phase-2 discussion and agreed on a streamlined Phase 3 design using lumbar spine and total hip BMD as surrogate primary endpoints at 12 months in roughly 750 women. Entera submitted the streamlined Phase 3 protocol to the FDA in March 2026. EB613 is currently the most credible oral non-GLP-1 peptide in late-stage development anywhere.
Rani Therapeutics takes a completely different approach. Instead of trying to dissolve a peptide and push it across the gut wall, the RaniPill is a swallowable robotic capsule. Small intestinal pH triggers a self-inflating balloon inside the capsule, which drives a dissolvable microneedle into the intestinal wall and delivers the drug directly into circulation. Effectively, it becomes a painless injection at the destination. Rani initiated Phase 1 of RT-114, a GLP-1 and GLP-2 dual agonist, in 2025, and in October 2025 announced a $1.085 billion partnership with Chugai. The company has reported that 19 preclinical molecules delivered via RaniPill achieved bioavailability comparable to subcutaneous injection. If that holds in humans, it would be the first "pill that is basically an injection" platform to make it to market.
Beyond those three, the MIT and Novo Nordisk academic work on gastric microneedle devices (SOMA, LUMI), along with ionic liquid carriers, lipid nanoparticles, and mesoporous silica systems, is all still preclinical or very early clinical.
The cautionary graveyard
Every honest look at the oral peptide market has to account for the programs that failed. The lesson from this list is that oral peptide drug development is not a problem you solve by putting peptide powder in a gel cap, even with a billion dollars behind you.
- Pfizer danuglipron, an oral small-molecule GLP-1, was discontinued in April 2025 after a single case of drug-induced liver injury in dose optimization. Pfizer had already dropped an earlier oral GLP-1, lotiglipron, in 2023. Pfizer is now out of the oral GLP-1 race entirely.
- 9 Meters Biopharma larazotide acetate, the most advanced oral peptide for celiac disease, saw its Phase 3 CeDLara trial halted at interim analysis in June 2022 when the independent statistician concluded the study could not feasibly hit significance. The failure ended the company's lead program.
- Oramed ORMD-0801, an oral insulin capsule, failed both primary and secondary endpoints in a 710-patient Phase 3 trial in January 2023. The stock dropped about 70 percent premarket and the type 2 diabetes program was discontinued.
- Tarsa Therapeutics TBRIA, an oral salmon calcitonin for postmenopausal osteoporosis, had a positive Phase 3. The NDA was accepted by the FDA in 2015. The product was never commercialized in the United States, and rights eventually moved offshore.
These were not underfunded programs. They had dedicated formulation chemistry, enteric coatings, permeation enhancers, and Phase 3 budgets. Oral peptide delivery is that hard.
Bioavailability tradeoffs
A clean way to see where the category actually sits:
| Route | Drug | Approximate bioavailability |
|---|---|---|
| Subcutaneous | Semaglutide | ~89% |
| Oral cyclic peptide | Cyclosporine | ~20 to 70% |
| Oral with SNAC | Rybelsus | ~0.4 to 1% |
| Oral with TPE | Mycapssa (octreotide) | ~0.7% |
| Oral or sublingual | Desmopressin | ~0.1 to 0.25% |
| Native oral peptide | Most therapeutic peptides | <0.1% |
Low bioavailability is not automatically a problem. If the formulation reliably hits target plasma levels and the cost of dosing up works out, a drug with 1 percent absorption can be a clinical and commercial winner. Rybelsus is proof of that.
The compliance paradox
Patients say they want pills. The REVISE study asked 600 people with type 2 diabetes whether they would prefer a daily oral GLP-1 or a weekly injection. Initially, 76.5 percent said they wanted the pill, with needle concerns and familiarity with tablets as the top reasons. But after learning the protocol details, including the empty stomach requirement and the 30-minute waiting period before food or other medication, roughly half of that group flipped back to preferring the weekly injection.
Real-world adherence data tells the same complicated story. In some cohorts, oral semaglutide shows one-year proportion of days covered around 82 percent, well above subcutaneous semaglutide at 39 percent in the same studies. In others, long-term persistence actually favors injectables by roughly 3 to 1, because the daily discipline of the Rybelsus protocol wears patients down in a way that a once-weekly injection does not.
The short version is that convenience cuts both ways. Daily discipline is not always easier than a weekly needle.
What about oral BPC-157 and other research peptides?
This is the section most people in the research peptide community actually care about, so it deserves a careful answer.
Oral BPC-157
BPC-157 has the strongest plausibility argument of any community research peptide for oral use because it was originally isolated from a fragment of a protective protein found in human gastric juice. Predrag Sikiric's lab in Zagreb has consistently reported that BPC-157 is stable in gastric acid for more than 24 hours, which is the entire biochemical case for oral dosing.
The rat evidence is extensive. Sikiric and collaborators have published dozens of studies giving BPC-157 orally in drinking water for gastric ulcer protection, NSAID-induced gut lesions, colitis models, short bowel syndrome, intestinal anastomosis healing, and more. A 2022 Frontiers in Pharmacology paper documented pharmacokinetics in rats and dogs, finding intramuscular bioavailability of roughly 14 to 19 percent in rats and 45 to 51 percent in dogs, with a plasma half-life under 30 minutes.
The human evidence, on the other hand, is essentially absent. The clinical-stage version of BPC-157, coded PL-14736, was tested as a rectal enema for ulcerative colitis, not as an oral capsule. A 42-volunteer Phase 1 pharmacokinetic trial was registered in 2015 (NCT02637284), and the sponsors withdrew the results submission in 2016. The data was never published. If oral BPC-157 had clean human PK, it is hard to imagine that data staying buried for a decade.
So the honest position on oral BPC-157 is this. There is a plausible mechanism, extensive rat data from one prolific lab, and zero published human pharmacokinetic data. Vendor capsules and troches ride on the "stable in gastric juice" claim, which is a real finding but does not by itself establish intestinal absorption, intact systemic delivery, or therapeutic plasma levels in humans.
KPV and locally acting oral peptides
KPV, the C-terminal tripeptide of alpha-MSH, has a more concrete oral mechanism than BPC-157 in one specific way. It is small enough to be transported by PepT1, a peptide transporter on intestinal epithelial cells that is upregulated in inflamed colon. Published rodent studies in colitis models show oral efficacy, and the mechanism for how a 3-amino-acid peptide could be delivered orally to inflamed gut is biologically credible. No human clinical trials have been published, but the logic for why it could work locally in the gut is cleaner than it is for most research peptides.
Everything else
For compounds like TB-500, GHK-Cu, CJC-1295, ipamorelin, epitalon, MOTS-c, and 5-amino-1MQ, there is no published human oral pharmacokinetic data. Vendor "oral" forms, including capsules, troches, and sublingual sprays, are sold on plausibility arguments, typically some mix of gastric stability, food-peptide-style absorption, and "small enough to cross the mucosa." None of those arguments has been verified by a published human PK study for any of these compounds.
The most defensible case for oral research peptides is for molecules that act locally in the gut and do not need to reach systemic circulation to do their job. BPC-157 for gut healing and KPV for gut inflammation both fit that category. Compounds that need to hit systemic plasma levels to work, including TB-500, GHK-Cu, and the GHRH and GHRP families, face the same chemistry problem it took Novo Nordisk a decade and a billion-dollar acquisition of Emisphere to solve for one molecule. Putting any of those compounds in a capsule does not make them orally active.
Sublingual, buccal, intranasal are not "oral"
One more thing to disambiguate, because vendor marketing constantly blurs it. Sublingual, buccal, and intranasal routes all bypass the digestive tract entirely. Desmopressin sublingual lyophilizate is a real approved product. Afrezza inhaled insulin is real. Intranasal delivery of Selank and Semax has published pharmacokinetic data in rodents. Oral delivery of those same compounds does not.
The hard problem, and the commercially interesting one, is specifically getting a peptide through the intestinal wall intact. A sublingual spray is not an oral tablet, and it should not be marketed as one.
The market and what comes next
Injectable GLP-1s currently make up roughly 93 percent of the overall GLP-1 market. Analysts expect the oral share to grow to something like one-third of an 80-billion-dollar-plus GLP-1 market by 2030, driven by Rybelsus expansion post-SOUL, the orforglipron launch, RaniPill clinical readouts, broader Medicare coverage of obesity treatment, and Entera Bio's EB613 Phase 3 readout on the osteoporosis side.
Injectables are not going away. Prefilled pens are getting cheaper, supply chains have caught up, and once-weekly dosing is sticky for patients who are already adherent. What is changing is that the oral option is moving from "exists for the needle-phobic" to "competitive on outcomes and scale."
Bottom line
"Oral peptides are here" is true, but the phrase means something specific. It means GLP-1s with permeation enhancers, octreotide with TPE, guanylate cyclase agonists that never need to reach the blood, an oral PTH tablet in late-stage trials, and cyclosporine as the one natural success story. These are drugs with billion-dollar formulation chemistry behind them.
Injectable peptides are being joined by oral options, not replaced. The next two to three years will reshape obesity, type 2 diabetes, acromegaly, and probably osteoporosis treatment.
For the research peptide community, the honest picture is narrower. No community peptide currently has published human oral pharmacokinetic data. The most defensible oral use cases are local gut effects from BPC-157 and KPV. For everything else, subcutaneous injection remains the only route with predictable absorption, and no amount of "oral" marketing on a capsule label changes that.
FAQ
Are oral peptides as effective as injections? Oral semaglutide just demonstrated a 14 percent reduction in major cardiovascular events in the SOUL trial, the same class of benefit seen with injectable semaglutide. So for that specific drug, yes. For other peptides, it depends entirely on whether the formulation actually delivers therapeutic plasma levels. Most of the time, it does not.
Why does Rybelsus require an empty stomach? The SNAC permeation enhancer needs a low-volume, food-free environment in the stomach to briefly fluidize the gastric epithelium and let semaglutide cross into circulation. Food, liquids over four ounces, or other medications all dilute and disrupt that process, and absorption drops sharply.
Is orforglipron a peptide? No. Orforglipron is a small molecule designed to activate the GLP-1 receptor. It delivers the same clinical effect as an oral peptide GLP-1 would, but it side-steps the oral peptide delivery problem entirely by not being a peptide. That matters when you are trying to understand what oral peptide technology can actually do.
Is there any published human evidence that oral BPC-157 works? No. There is extensive rat data from one lab, a plausible mechanism rooted in BPC-157 being a gastric juice fragment, and a 42-volunteer Phase 1 human pharmacokinetic trial that was registered in 2015 and never published. The clinical-stage form of BPC-157 was tested as a rectal enema, not an oral capsule.
Are vendor "oral" forms of TB-500, GHK-Cu, or CJC-1295 absorbed? There is no published human pharmacokinetic data for oral versions of any of those compounds. Vendor claims rely on plausibility arguments rather than measured absorption. The safe assumption is that the injectable route remains the only form with predictable exposure.
